Cancer BiologybioRxivPreprint
MYC overexpression drives poor prognosis and differential sensitivity to treatments according to TP53 status in chronic lymphocytic leukemia
Alba Garrote-de-Barros, Juan Pérez‐Fernández, Andrés Arroyo-Barea…·María Hernández‐Sánchez
This study shows that MYC overexpression in CLL worsens prognosis and treatment response, with different effects based on TP53 status.
DOI 10.64898/2026.05.14.724995